With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

AstraZeneca PLC announced that Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) ...

AstraZeneca PLC through Alexion, AstraZeneca Rare DiseasesUltomiris(ravulizumab) was approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

Alexion, AstraZeneca Rare Disease?s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression ...

Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the U.S. to reduce proteinuria in adults ...

Alexion unit's Ultomiris received the US Food and Drug Administration accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression, the company said ...

Alexion, AstraZeneca Rare Disease, has announced US FDA accelerated approval of Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy a ...

A new bipartisan bill aims to speed rare disease drug development by making clinical trials faster, cheaper and more ...

Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy Based on I CAN Phase III trial ...

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic ...

Alexion, AstraZeneca Rare Disease's Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A ...